ALN-AAT in Healthy Volunteers and Patients with Alpha-1 Antitrypsin Deficiency Liver Disease

Phase 1, randomised, single-blind trial in alpha-1 antitrypsin deficiency (AATD) comparing ALN-AAT with Placebo (2 arms). Primary endpoint: Proportion of subjects experiencing adverse events (AEs), serious adverse events (SAEs), and AEs leading to study drug discontinuation at Day 224. Started Jul 2015; status: terminated.